Skip to main content

The Globe and Mail

Galectin Therapeutic (GALT-Q) Quote

Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 2.39
Day High 3.10
Open:3.06
Price movement based on the high, low and last over the given period.
Previous Close
Volume
Average Volume
Price/Earnings (TTM)
Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Description
Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share ttm
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings ttm
Annual Dividend & Yield
Ex-Div Date
Price/Book
Most Recent Split

Financials

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Latest Press Releases

Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
GlobeNewswire - Mon Nov 13, 8:02AM CST
GlobeNewswire - CMTX
Mon Nov 13, 8:02AM CST
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D., the Company's chief executive officer and chief medical officer, has been named the Chair of the Anti-Fibrotic Drug Development Summit 2017. The Summit, which is dedicated to the translation of fibrotic mechanisms into clinically effective therapeutics, will take place November 13-14 at the Hyatt Regency Boston, Boston, MA.
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
GlobeNewswire - Mon Nov 13, 8:00AM CST
GlobeNewswire - CMTX
Mon Nov 13, 8:00AM CST
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
GlobeNewswire - Mon Nov 13, 7:30AM CST
GlobeNewswire - CMTX
Mon Nov 13, 7:30AM CST
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.20 +13.64% increase
on 11/02/17
Period Open:2.66
Price movement based on the high, low and last over the given period.
3.14 -20.38% decrease
on 11/20/17
-0.16 (-6.02%) decrease
since 10/20/17
3-Month 1.63 +53.37% increase
on 09/15/17
Period Open:1.73
Price movement based on the high, low and last over the given period.
3.14 -20.38% decrease
on 11/20/17
+0.77 (+44.51%) increase
since 08/21/17
52-Week 0.81 +208.64% increase
on 11/30/16
Period Open:0.97
Price movement based on the high, low and last over the given period.
3.68 -32.07% decrease
on 04/10/17
+1.53 (+157.73%) increase
since 11/21/16

All market data is provided by Barchart Solutions (will open in new tab). Copyright © 2017.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).